Related Experiment Videos
Mortality from neuroleptic malignant syndrome.
A Shalev1, H Hermesh, H Munitz
1Department of Psychiatry, Gehah Psychiatric Hospital, Tel Aviv University, Israel.
The Journal of Clinical Psychiatry
|January 1, 1989
Summary
Mortality from neuroleptic malignant syndrome (NMS) has significantly decreased since 1984. Key risk factors for NMS mortality include organic brain syndrome, myoglobinemia, and renal failure.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Neuroleptic Malignant Syndrome (NMS) is a rare but severe adverse reaction to antipsychotic medications.
- Assessing mortality trends and risk factors is crucial for improving patient outcomes.
Purpose of the Study:
- To analyze mortality rates associated with NMS.
- To identify risk and protective factors influencing NMS mortality.
Main Methods:
- Exhaustive review of 202 published case reports on NMS.
- Differential assessment of risk and protective factors.
- Statistical analysis of mortality trends and associated conditions.
Main Results:
- Significant decrease in NMS mortality since 1984 (11.6% vs. 25% previously).
- Mortality from haloperidol-induced NMS is significantly lower (7%).
- High mortality (38.5%) observed in patients with organic brain syndrome.
- Myoglobinemia and renal failure are strong predictors of mortality (approx. 50% risk).
Conclusions:
- NMS mortality has declined, independent of specific treatments like dopamine agonists or dantrolene.
- Organic brain syndrome, myoglobinemia, and renal failure significantly increase NMS mortality risk.
- Findings have implications for clinical management and risk stratification in NMS patients.